Cordlife Group (SG:P8A) has released an update.
Cordlife Group Limited has been directed by the Ministry of Health to halt its cord blood and human tissue services due to non-compliance with healthcare regulations. The company is actively working on rectification measures, establishing an oversight committee and a Medical and Technical Advisory Board to address the issues. They have also partnered with Shandong Qilu Stemcell Engineering to assist in improving their operations during this period.
For further insights into SG:P8A stock, check out TipRanks’ Stock Analysis page.
